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SUMMARY
In recent years, Artemisinin and particularly one of its derivatives - Artesunate (ART - has become an essential alternative for
treatment of both uncomplicated and severe falciparum malaria in Asia and Africa as well.
Therefore, these compounds are still and inccreasingly in the focus of interest because of quick acting of this drug, is able to help
even unconscious to overcome the malaria attack, when administered by injection. As an alternative, RECTOCAPS have been
developed and their use is meanwhile well established. From earlier studies in children, suffering from plasmodium falciparum
malaria, we obtained a high level of DHART in the blood, but as expected also a rapid decline in the levels of both DHART and
ART. A second administration of ART was additionally applied 4 hours after the first administration. DHART and ART plasma
levels were found to last longer on an assumed therapeutic level than those obtained after one administration only. The fever
clearance and the parasitemia reduction rates were found to be effective according to this dosing regimen. In view of these
findings, we decided to conduct the actual described study by administering 200 mg of ART every 3 hours (0, 3, 6 and 9 h) by the
rectal route.
Soft geiatine capsules (RECTOCAPS) containing 200 mg of ART GMP - type each (Artesunic acid) were administered by rectal
route. Each patient received four RECTOCAPS capsules (4 x 200 mg of ART) over a 3 h period.
12 adult patients with uncomplicated malaria were selected. Age, weight, height, body temperature, parasite counts before
treatment and their evolution until 96 h are determined. Blood samples were taken at short time intervals after starting with the
first medication: 0, 30 min, 60 min, 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, 48 h, 60 h, 72 h, 84 h, 96 hand 108 h. The aliquots of all the blood
samples were used for performing parasite counts. Plasma obtained following the traditional procedure was kept at -40°C until
analysis. HPLC technique with electrochemical detector was used for quantification of ART and DHART. From the blood
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concentration values of ART and DHART, the following observation can be derived: the onset of action is observed within the
first half hours, therapeutic levels of the drug obtained (89 Itg/ml ART compared to 84 ugjrnl DHART). The DHART levels are
somewhat higher than those of ART (a peak concentration after 6 h starting medication of 151 ug/ml ART as compared to 276
Itg/ml DHART). The variations as a function of frequency of DHART uptake are much less marked than those observed for ART.
Another finding is that after the administration, some sort of a plateau of DHART and ART is built up, lasting at least from 9 to 12
hours with DHART level of about 190 Itg/ml and ART of 90 Itg/m\. In the case of single-dose administration, the levels of both
compounds were below the detection threshold after three hours.
With regard to the parasite counts, although there were inter-individual variations, it should be noted that after 48 hours a high
proportion of the patients (8 out of 12) was completely clear of parasites. Similar results were observed with regard to the body
temperature (7 out of 12 returned to normal temperature 36 hours after starting the therapy). The findings of the study support the
RECTOCAPS application principle resulting in effectiveness both for the velocity of drug uptake as well as for the height of
plasma levels. Repeated administration of ART can extend the duration of therapeutic plasma levels of the drug.
INTRODUCTION
In recent years, Artemisinin and particularly one of its
derivatives - Artesunate - has become an essential
alternative for both uncomplicated and severe falciparum
malaria in Asia and Africa.
The use of these drugs has become more frequent in
other parts of the world as wellin spite of the extraordinary
therapeutic success of this therapy, its use is not nearly as
widespread as it deserves to be. There are a number of
reasons for this, the first of which is that the cost of this
medication is still relatively high for the populations in
developing countries that are in need of it. However there
are indications that the price willbe substantially reduced
in the near future. Another factor that has impeded the
adoption of Artesunate is the claim made by some
international bodies, that wider use of these drugs would
lead to resistance of the parasite. It should be borne in
mind, however, that there is sufficient evidence that the
Artemisinin family of drugs has a mode of action that is
totally different from that of the classicalantimalaria drugs
to whichthe resistance phenomenon has been established.
Furthermore, since 1985, millions of people in China and
Vietnam have been treated with drugs of this family with
no cases of resistance reported.
On this point, homage should be paid to our Chinese
colleagues for their extraordinary discovery that they
saved the lives of millions of malaria patients.
Nevertheless, the high rate of recrudescence reported
by several authors (1,2,3,4) remains a problem. The
Chinese schema for treatment of uncomplicated malaria
by the administration at 0, 4, 24 and 48 hours have resulted
in a recrudescence rate from 45 to 60 % (5). However,
other studies conducted at the same period of time, have
reported a recrudescence rate of only 5 % when the
treatment lasted for 5 days (5). These authors suggested
that another antimalarial (Mephloquine) be administered
after the 3 days of treatment with artemisinin and
derivatives to reduce the high rate of recrudescence..
At the time that these results were reported, no reliable
pharmacokinetic data were available. It is now known
that the pharmacokinetics of artemisinin and derivatives
are directly related to the therapeutic effect. In one of our
studies in children with plasmodium falciparum malaria,
we observed not only a high level of dihydroartemisinin
in the blood but also a rapid decline in the levels of
dihydroartemisinin and artesunate and that 4 hours after
the first administration, the level for both compounds were
below the detection levels. A second administration of
artesunate was given 4 hours after the first administration.
The dihydroartemisinin and artesunate values,measured
1 hr later were found to be practically the same as those
obtained after the first administration, the fever clearance
and the parasitemia rates were also found to be surprisly
good.
In view of these very encouraging results, we decide to
conduct the study reported in this paper, in which 200 mg
of artesunate was administered every 3 hours (0, 3, 6 and
9 h) by rectal route (RECTOCAPS suppositories).
EXPERIMENTAL CONDITIONS AND
SUBJECTS OF THE STUDY
The protocole of this study has been approuved by the
local ethics committee.
12 adult patients with uncomplicated malaria were
selected. Age, weight, sex, height and body temperature
before start of treatment are shone Table I. Parasite counts
before treatment and their evolution until 96 hrs are given
in Table II.
Soft gelatine ampoules (RECTOCAPS from MEPHA
Company) containing 200 mg of Artesunate (Artesunic
acid) were administered by rectal route. Each patient
received four RECTOCAPS ampoules (4 x 200 mg of
Artesunate) ever a 3 h period. Since the study was designed
to establish the pharmacokinetic parameter values of
Artesunate under conditions of repeated administration,
blood samples were taken at the following time intervals:
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Table I: Temperature Chart for the 12subjects (taken every 12 hours)
N° 101 102 103 104 105 106 107 108 109 110 111 112
Age 37 25 40 50 37 24 36 19 49 52 42 46
Weight 44 38 34 53 44 64 38 51 70 52 485 53
Height 165 145 157 165 163 171 145 169 165 153 157 156
715/400 1815/37.6° 640/38° 1730/38° 9/39° 17/38.2° 1535/39° 640/37° 2(}'lJ/39° 730/37° tQ45/405° 1840/38°
1915/38° 615/38° 1840/37.2° 530/38.2° 21/38.2° 5/395° 335/37° 1840/37.2° 830/39° 1930/37° 2245/38.5° 640/37°
715/37.2° J815/37.2° 640/38.4° 1730/37.5° 9/38.5° 17/40° 1535/38.5° 640/36.8° 2(}'lJ/4oo 730/385° t<)"5/405° 1840/39°
1915/36.8° 615/365° 1840/365° 530/36.8° 21/37.2° 5/40° 335/36.5° 1840/37.2° 830/39.2° 1930/37.2° 2245/36.5° 640/37.5°
715/37° 640/37.5° 9/36.8° 17/37.2° 1535/37.2° 640/38.4° 2(}'lJ/365° 730/37° lQ45/37.2° 1840/36.8°
1840/39.6° 21/36.4° 5/36.2° 335/36.5° 1840/37.5° 830/36.8° 1930/37.2° 2245/36.8° 64°/37°
64°/37.2° 9/36.8° 1535/36.8° 640/38.5° 2(}'lJ/36.5° 730/37° lQ45/37° 1840/36.8°
1840/375° 32/36.8° 335/37° 1840/37° 830/37.4° 2245/37° 2245/37°
640/36.5° 9/37° 640/37° 2(}'lJ/37°
1840/37.2° 830/37°
640/37°
36h 36h 48h 36h 36h 48h 36h 84h 48h 36h 48h 48h
Table II: Parasite Counts
Sex M F F M M M M M M F F F
Age 37 25 40 50 37 24 36 19 49 52 43 46
Weight 44 38 34 53 44 64 38 51 70 52 48.5 53
Height 165 145 157 165 163 171 145 169 165 153 157 156
0 561 155000 37600 4697 643 110714 zcooo 1925 7778 743 26458 58333
30' 552 119231 35878 4189 620 110714 17241 1845 6774 584 20934 52128
60' 566 103333 30322 3726 627 103353 16854 1540 5250 573 19639 48039
3h 534 59615 29560 3563 567 10353 13043 1265 2646 496 19050 37692
6h 506 32667 22927 3183 559 91177 12605 1183 2142 336 17972 28488
9h 483 16667 18990 2217 544 86111 12000 908 92 177 17009 26630
12h 423 7831 17296 78 544 73810 11364 660 38 7 19050 2058
24h 561 465 5978 6 537 67391 7143 110 4 0 17318 98
36h 423 372 5189 0 38 899 2467 0 0 0 103 0
48h 184 0 2256 0 0 28 510 0 0 0 11 0
60h 9 0 1880 0 0 0 135 0 0 0
72h 0 0 0 0 30 0 0
84h 0 0 0
96h 0 0
108h 0
60h 48h 72h 30h 48h 60h 84h 48h 36h 24h 60h 36h
0,30 min, 60 min, 3 h, 6 h, 9 h, 12h, 24 h, 36 h, 48 h, 60 h,
72 h, 84 h, 96 h and 108 h.
The aliquots of all the blood samples were used for
parasite counts. Plasma obtained after traditional
procedure was kept at -40°C until analysis. HPLC
technique with electrochemical detector was used for
quantification of Artesunate and Dihydroartemisinin. The
experimental conditions (colonne, mobil phase, internal
standard etc) have been described in detail in one of our
previous publications (5).
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RESULTS AND DISCUSSION
The blood level values of artesunate and dihydroartemisinin
are shown in Fig. 1. From these results, two important
observations can be made. First,that the dihydroartemisinin
levels are substantially higher than those of artesunate
(about 2 x higher) and also that the variations as a function
of frequency are much less marked than those observed
for artesunate.
The second note worthy point is that in spite of the
relatively limited number of administrations, a plateau of
dihydroartemisinin (of about 200 ug/ml) was obtained and
this was also true for artesunate although with slightly
lower values.
It should also be noted that 12 hours after this first
administration of RECTOCAPS the average dihydroarte-
misinin level was about 200 I-lg/ml and about 100 I-lg/ml
for artesunate.
These values should be considerer in the light of finding
that in the case of a single administration, the levels of
both compounds were below the detection threshold after
only three hours.
With regard to the parasite counts, although there were
inter-individual variations, it should be noted that after 48
hours most of the patients (8 out of 12) were completely
clear of parasites and after 60 hours only 2 patients stilI
had parasites. Similar favourable results were observed
with regard to temperature (7 out of 12returned to normal
temperature 36 hours after the start of therapy (Table I).
The same experimental protocol has been used in 8
patients with severe malaria. Although the parasite counts
and the temperature values are very similar to those found
in patients with uncomplicated malaria, it was
unfortunately not possible to quantify artesunate and
dihydroartemisinin because the analytical technique used
was not adequate for blood samples with a high hemolysis
rate as is the case in severe malaria patients.
The findings of this study are very encouraging, not only
because the clearly show the effectiveness of repeated
administration of Artesunate in the form of RECTOCAPS
but also and more importantly, because they strongly
suggest that it wouldbe of great interest to conduct a further
study of which the protocol would be specificallydesigned
to investigate the effect of frequent administration on
recurrency.
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